Short answer
FATE THERAPEUTICS INC (FATE) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2M (up 9.2% year over year) with net income of −$30M.
Q2 2026 key financials · XBRL
- Revenue
- $2M
- +9.2% YoY · +60.3% QoQ
- Net income
- −$30M
- +11.5% YoY · +3.4% QoQ
- Operating margin
- -1495.4%
- EPS (diluted)
- −$0.25
- +13.8% YoY · +3.8% QoQ
Source: XBRL data from the FATE THERAPEUTICS INC (FATE) Q2 2026 10-Q on SEC EDGAR. USD.
FATE THERAPEUTICS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $2.1M, up from $1.9M YoY
- Research and development expense $24.4M, down from $27.4M YoY
- General and administrative expense $8.8M, down from $11.4M YoY
- Clinical trial expense increased $1.7M, offsetting lower compensation and consulting costs
- Cash outlook supported by $7.9M FT819 and $4.0M FT836 CIRM awards; funding sufficient for at least twelve months
Risk Factors
- FDA’s May 2026 selection of FT819 for the CDRP Program created reliance on enhanced CMC engagement without assurance of faster development
- Manufacturing risk heightened by unvalidated commercial-scale processes and potential FDA-required process changes
- Regulatory approval risk remains acute because no product candidate has completed clinical development or received approval
- Clinical execution risk from patient recruitment, competing trials, and potential clinical holds
- Supply concentration risk from dependence on internal San Diego facilities and third parties for manufacturing components
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FATE THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.